Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model.
- Author:
Gaewon NAM
1
;
Se Kyoo JEONG
;
Bu Man PARK
;
Sin Hee LEE
;
Hyun Jong KIM
;
Seung Phil HONG
;
Beomjoon KIM
;
Bong Woo KIM
Author Information
- Publication Type:Original Article
- Keywords: Atopic dermatitis; Cannabinoid receptor agonists; Histamine; Mast cells
- MeSH: Animals; Basophils; beta-N-Acetylhexosaminidases; Cannabinoid Receptor Agonists; Cannabinoids; Cell Line; Cytokines; Dermatitis, Atopic*; Dermatitis, Contact; Histamine; Immunoglobulin E; Immunoglobulins; Inflammation; Interleukins; Leukemia; Mast Cells*; Mice; Peptide Hydrolases; Psoriasis; Rats; Skin; Tumor Necrosis Factor-alpha
- From:Annals of Dermatology 2016;28(1):22-29
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Many inflammatory mediators, including various cytokines (e.g. interleukins and tumor necrosis factor [TNF]), inflammatory proteases, and histamine are released following mast cell activation. However, the endogenous modulators for mast cell activation and the underlying mechanism have yet to be elucidated. Endogenous cannabinoids such as palmitoylethanolamide (PEA) and N-arachidonoylethanolamine (anandamide or AEA), were found in peripheral tissues and have been proposed to possess autacoid activity, implying that cannabinoids may downregulate mast cell activation and local inflammation. OBJECTIVE: In order to investigate the effect of cannabinoid receptor-1 (CB1R) agonists on mast cell activation, AEA-derived compounds were newly synthesized and evaluated for their effect on mast cell activation. METHODS: The effects of selected compounds on FcepsilonRI-induced histamine and beta-hexosaminidase release were evaluated in a rat basophilic leukemia cell line (RBL-2H3). To further investigate the inhibitory effects of CB1R agonist in vivo, an oxazolone-induced atopic dermatitis mouse model was exploited. RESULTS: We found that CB1R inhibited the release of inflammatory mediators without causing cytotoxicity in RBL-2H3 cells and that CB1R agonists markedly and dose-dependently suppressed mast cell proliferation indicating that CB1R plays an important role in modulating antigen-dependent immunoglobulin E (IgE)-mediated mast cell activation. We also found that topical application of CB1R agonists suppressed the recruitment of mast cells into the skin and reduced the level of blood histamine. CONCLUSION: Our results indicate that CB1R agonists down-regulate mast cell activation and may be used for relieving inflammatory symptoms mediated by mast cell activation, such as atopic dermatitis, psoriasis, and contact dermatitis.
